A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)
Latest Information Update: 03 Aug 2024
At a glance
- Drugs TAK 653 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms SAVITRI; SAVITRI STUDY
- Sponsors Neurocrine Biosciences
- 01 Aug 2024 According to a Neurocrine Biosciences Media Release, the company is Conducting End of Phase 2 Meeting with FDA and plans to initiate phase 3 trial in 2025.
- 23 Apr 2024 Primary endpoint (Change from Baseline in Total Montgomery sberg Depression Rating Scale (MADRS) Score at Day 28) has been met, according to a Neurocrine Biosciences Media Release.
- 23 Apr 2024 According to a Neurocrine Biosciences Media Release, additional data from the SAVITRI study will be shared at a future scientific conference.